

## QIBA Proton Density Fat Fraction Biomarker Committee (PDFF BC) Update Call

Thursday, March 1, 2018 at 3 PM (CT)

### Call Summary

#### Participants

Scott Reeder, MD, PhD (Co-chair)

Gavin Hamilton, PhD

Nancy Obuchowski, PhD

#### RSNA

Joe Koudelik

Takeshi Yokoo, MD, PhD (Co-chair)

Michael Middleton, MD

Elif Sikoglu, PhD

Susan Stanfa

Mustafa Bashir, MD

#### Review of Previous Call Summary

- The 02.01.2018 call summary was approved as presented

#### Profile

- We discussed what would be needed for a new PDFF MRI method to demonstrate QIBA-conformance in terms of variability and bias
  - To demonstrate QIBA conformance to the Longitudinal Claim in the PDFF Profile, test-retest repeatability measurements in human subjects would be needed to confirm that variability is within a defined, acceptable range, with 95% confidence
  - The “acceptable range” of repeatability coefficient should be similar to what was shown in meta-analysis; details to be discussed
  - Bias is more complicated than variability; if there were a perfect reference standard for PDFF, a cross-sectional bias Claim could be made
    - We discussed the use of spectroscopy (MRS) or previously-validated MRI methods to demonstrate Profile conformance
    - Simulations by Dr. Obuchowski showed that if the reference standard contain variability (i.e. imperfect reference standard, like MRS or previously-validated MRI), there is an unacceptably high probability of misclassifying new PDFF methods as Profile-conformant
    - Developing a new standardized physical phantom to demonstrate conformance may be sufficient; more discussion is needed regarding such a reference standard

#### Repeatability

- In vivo conformance tests for repeatability needs to include sufficient number of patients across the range of clinically-relevant PDFF range (from 0% to approx. 30%)
  - Conformance test needs to demonstrate that the standard deviation is constant across the full range of clinically-relevant PDFF values – i.e. conformance limited to PDFF 0-5% range is not acceptable
  - Dr. Obuchowski to provide guidance for study design and sample size determination

## **Bias**

- Fat-water phantoms with known PDFF values using phantom-specific recon protocol should be required but may not be sufficient
  - We discussed whether human testing for bias conformance is needed or phantom only is sufficient.
  - Some members felt strongly that some sort of human testing is needed in addition to phantom
  - An acceptable clinical “reference standard” such as in vivo spectroscopy or previously-validated MRI (an imperfect reference standard, but may be an acceptable reference standard for bias)?
  - MR spectroscopy or previously-validated MRI may have bias from true PDFF because it is an experimental instrument; it is an imperfect reference standard
  - When an imperfect reference standard is used as a bias reference standard, the percent of errors in determining QIBA conformance is too high (see above comments re Simulation results)
  - Therefore, the group is inclined to use phantom for formal bias conformance testing, and use spectroscopy or previously-validated MRI to test linearity in vivo. We can require the new PDFF technique to have a linear correlation coefficient above certain value against spectroscopy or previously-validated MRI.

## **Standard Reference Object for Bias (i.e. Phantom)**

- Would need to conduct additional, round-robin multivendor study to determine bias (acquisition and reconstruction for each scanner needed), with vendor-specific recons
- Phantoms may help identify imaging sites that implement the Profile correctly, i.e., conformant sites
- Specs for phantom development to be provided
- Suggestion to collaborate with [Calimetrix](#), as it has the only commercial fat phantom on the market
  - Discussion on how to fund the Calimetrix phantom
  - Discussion of how to address possible conflict of interest for Dr. Reeder (Co-founder of Calimetrix)
  - Disclaimer will be drafted to acknowledge conflict of interest and explain how the issue will be navigated, i.e.:
    - Some boundary between Dr. Reeder and this project needed
    - Data cannot be housed at the University of Wisconsin-Madison
    - Data may be stored and analyzed by an independent party
- Dr. Reeder to discuss this possible collaboration with Calimetrix colleagues
- Additional discussion needed regarding the range of fat fractions for phantoms

- Drs. Yokoo and Obuchowski to collaborate on the statistical issues on the repeatability and linearity testing

**Next call: Thursday, April 5, 2018 at 3 PM CT**

---

RSNA Staff attempt to identify and capture all committee members participating on WebEx calls. However, **if multiple callers join simultaneously or call in without logging on to the WebEx, identification is not possible.** Call participants are welcome to contact RSNA staff at [QIBA@RSNA.org](mailto:QIBA@RSNA.org) if their attendance is not reflected on the call summaries.